SCHEMBL4924112

SCHEMBL4924112

CC(C)(C)OC(=O)N1CCCc2cc(N)ccc2C1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.77
ESR2 Q92731 1/20 0.63
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HDAC6 Q9UBN7 1/20 0.47
MAPK1 P28482 1/20 0.46
RIPK1 Q13546 3/20 0.46
HDAC1 Q13547 1/20 0.45
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
BRD4 O60885 1/20 0.42
ATAD2 Q6PL18 1/20 0.42
HSD17B3 P37058 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA1 P30542 1/20 0.41
NAMPT P43490 3/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928220 0.95 NR1H2 (0.85) NR1H2ESR2NPC1RAB9AHDAC6
SCHEMBL61143 0.92 NR1H2 (0.90) NR1H2ESR2NPC1RAB9AHDAC6
SCHEMBL29377835 0.92 NR1H2 (0.90) NR1H2ESR2NPC1RAB9AHDAC6
SCHEMBL29507781 0.87 NR1H2 (1.00) NR1H2ESR2NPC1RAB9AMAPK1
SCHEMBL308035 0.87 NR1H2 (1.00) NR1H2ESR2NPC1RAB9AMAPK1
SCHEMBL29803773 0.86 NR1H2 (0.80) NR1H2ESR2MAPK1HDAC1DDB1
SCHEMBL520400 0.86 NR1H2 (0.80) NR1H2ESR2MAPK1HDAC1DDB1
SCHEMBL3702146 0.86 ESR2 (0.85) NR1H2ESR2NPC1RAB9AHDAC6
SCHEMBL1263385 0.85 ESR2 (0.63) NR1H2ESR2NPC1RAB9AHDAC6
SCHEMBL2984097 0.85 ESR2 (0.63) NR1H2ESR2NPC1RAB9AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2016-06-09 US disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors CAMUS LAURE 2008-12-11 US disclosed
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors CAMUS LAURE 2008-12-11 US disclosed
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors CAMUS LAURE 2008-12-11 US disclosed
US-20080063628-A1 METHODS TO PROMOTE CELL DIFFERENTIATION LIFESCAN, INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306045-A1 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors TFPI, TPSAB1, TFPI2 NR1H2 789/4885ESR2 1283/4885NPC1 2067/4885
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 NR1H2 557/4885ESR2 2068/4885NPC1 48/4885
US-20080063628-A1 METHODS TO PROMOTE CELL DIFFERENTIATION CTCF, CBX2, ZMYND8 NR1H2 995/4885ESR2 1540/4885NPC1 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.